Цитата:
Results
A total of 61 684 persons with at least a 240‐day supply of medication (34 178 pantoprazole and 27 686 other PPIs) were followed up for a total of 547 020 person‐years (274 700 vs. 272 321 person‐years, respectively). The primary analyses demonstrated comparable risks between the pantoprazole and other PPI groups for gastric cancer [hazard ratio (HR) = 0.68, 95% CI 0.24–1.93); colorectal, liver, pancreatic, or small bowel cancers (HR = 0.95, 95% CI 0.65–1.40) or any cancer (HR = 1.06, 95% CI 0.93–1.21).
Conclusions
We found no evidence that pantoprazole, a longer acting PPI, compared with shorter‐acting agents, conferred an excess risk of gastric cancer, other gastrointestinal cancers or all cancers for pantoprazole compared with other shorter‐acting PPIs.
С чего вы вообще взяли,что какая то связь есть?